Table 1.
Clinical characteristics of patients in Nanostring cohort after QC and normalisation
| Characteristic | All (N = 158) | Responder (N = 90) | Non-responder (N = 68) | P-value | |
|---|---|---|---|---|---|
| Patients with repeats, N | 5 | 3 | 2 | ||
| Additional repeats, No | 7 | 4 | 3 | ||
| Treatment, N. (%): | IPI + PD1c | 74 (46.8) | 47 (52.2) | 27 (39.7) | 0.1615a |
| PD1c | 84 (53.2) | 43 (47.8) | 41 (60.3) | ||
| Biopsy sites, N. (%): | 0.1461b | ||||
| Brain | 15 (9.5) | 9 (10) | 6 (8.8) | ||
| Liver | 2 (1.3) | 2 (2.2) | |||
| Lung | 7 (4.4) | 4 (4.4) | 3 (4.4) | ||
| Lymph node | 44 (27.8) | 21 (23.3) | 23 (33.8) | ||
| Mucosa | 2 (1.3) | 2 (2.9) | |||
| Primary | 6 (3.8) | 5 (5.6) | 1 (1.5) | ||
| Small bowel | 3 (1.9) | 2 (2.2) | 1 (1.5) | ||
| Subcutaneous | 73 (46.2) | 41 (45.6) | 32 (47.1) | ||
| Other | 6 (3.8) | 6 (6.7) |
N indicates number
aPearson’s Chi-squared test with Yates’ continuity correction
bPearson’s Chi-squared test
cIPI: ipilimumab; PD1: nivolumab or pembrolizumab